Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

13.2%

7 terminated out of 53 trials

Success Rate

78.8%

-7.7% vs benchmark

Late-Stage Pipeline

17%

9 trials in Phase 3/4

Results Transparency

23%

6 of 26 completed with results

Key Signals

6 with results79% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (2)
P 1 (12)
P 2 (6)
P 3 (6)
P 4 (3)

Trial Status

Completed26
Unknown10
Terminated7
Recruiting5
Withdrawn3
Active Not Recruiting2

Trial Success Rate

78.8%

Benchmark: 86.5%

Based on 26 completed trials

Clinical Trials (53)

Showing 20 of 20 trials
NCT01386437Recruiting

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT05101187Phase 3Active Not RecruitingPrimary

Olorofim Aspergillus Infection Study

NCT04550936CompletedPrimary

A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.

NCT04486885Completed

European Study of Cerebral Aspergillosis Treated With Isavuconazole

NCT05707832Phase 3Completed

A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus

NCT03717623Phase 4Recruiting

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

NCT04218851Phase 2CompletedPrimary

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

NCT06583512Active Not RecruitingPrimary

Treatment Duration of IPA

NCT03816176Phase 2Completed

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

NCT02646774Phase 4TerminatedPrimary

Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis

NCT06069505RecruitingPrimary

Detection of Azole Resistance Inducing Mutations on DNA Extracted Directly From Serum or Plasma of Immunocompromised Patients With an Invasive Aspergillus Infection Azole Resistance PCR Optimalization-study

NCT04876716Phase 3TerminatedPrimary

Azole-echinocandin Combination Therapy for Invasive Aspergillosis

NCT06382922RecruitingPrimary

Role of Antifungal Prophylaxis in Elderly Patients With Acute Myeloid Leukemia During Consolidation Therapy

NCT06344117RecruitingPrimary

Assessment of Volatile Organic Compounds (VOC) for the Diagnosis of Invasive Aspergillosis (IA) in Lung Transplant Recipients

NCT06028451UnknownPrimary

ManagemEnt of Antifungal Drug in Invasive Aspergillosis:a Real-word Study

NCT03221075CompletedPrimary

Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy

NCT03014934UnknownPrimary

Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation

NCT01695512UnknownPrimary

Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients

NCT01448226CompletedPrimary

Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy

NCT02104479UnknownPrimary

Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing

Scroll to load more

Research Network

Activity Timeline